Pentosan Polysulfate Sodium (PPS) From Bladder Pain to Broad-Spectrum Tissue Protection A Comprehensive Academic Review

Pentosan Polysulfate Sodium (PPS) From Bladder Pain to Broad-Spectrum Tissue Protection A Comprehensive Academic Review

Mechanisms • Clinical Evidence • Functional Medicine Applications

Yoon Hang Kim, MD, MPH  |  April 2026

Introduction

Pentosan polysulfate sodium (PPS) is one of the most mechanistically fascinating and clinically underappreciated molecules in modern pharmacology. Best known to American clinicians as Elmiron—the sole FDA-approved oral therapy for interstitial cystitis—PPS has a far richer identity. It is a broad-spectrum tissue-protective molecule with a portfolio that spans chondroprotection, microvascular repair, antiviral activity, antiparasitic effects, and regenerative support.

This review provides a comprehensive examination of PPS for the functional and integrative medicine clinician. We begin with the chemistry and classification—correcting common misconceptions that PPS is a peptide or glycoprotein. We then survey its FDA-approved use, explore the remarkable molecular biology of PPS in arthritis (including its dual-mechanism attack on cartilage-degrading enzymes), detail its broad antimicrobial spectrum, review additional pleiotropic applications in functional medicine, and close with the critical safety considerations that every prescribing clinician must understand.

A unifying thread runs through this entire review: PPS is a glycosaminoglycan (GAG) mimetic, and nearly all of its therapeutic effects follow from that single structural identity. Whether the target is a cartilage-degrading enzyme, a viral spike protein, a bacterial adhesin, or a misfolded prion, PPS engages the same fundamental biology: the heparan-binding interactions that pervade human physiology and pathology.

PART I — WHAT IS PENTOSAN POLYSULFATE?

Chemistry and Classification

Patients and even some practitioners occasionally refer to PPS as a peptide or a glycoprotein. It is neither. PPS is a semi-synthetic sulfated polysaccharide—a heparin-like macromolecular carbohydrate derivative synthesized from beechwood hemicellulose (xylan). Chemically, it consists of repeating β-(1→4)-linked xylose units that have been sulfated at their hydroxyl groups, producing a highly negatively charged polyanion with a molecular weight of approximately 4,000 to 6,000 Daltons.

To clarify the terminology: a peptide is a short chain of amino acids; a glycoprotein is a protein with carbohydrate side chains. PPS contains no amino acids and no protein component. It belongs to the family of glycosaminoglycan (GAG) mimetics—compounds that structurally and functionally resemble the naturally occurring GAGs (heparan sulfate, chondroitin sulfate, hyaluronic acid) that coat cell surfaces and populate the extracellular matrix throughout the body. This GAG-mimetic identity is precisely what gives PPS its remarkable breadth of biological activity.

PART II — FDA-APPROVED INDICATION: INTERSTITIAL CYSTITIS

Interstitial Cystitis / Bladder Pain Syndrome

PPS received FDA approval in 1996 as the sole oral medication indicated for the relief of bladder pain and discomfort associated with interstitial cystitis (IC), also known as bladder pain syndrome. IC is a chronic inflammatory condition characterized by urinary frequency, urgency, and pelvic pain in the absence of identifiable infection or other pathology.

The proposed mechanism in IC is conceptually elegant: the healthy bladder is lined by a protective glycosaminoglycan layer that prevents urine solutes from penetrating and irritating the underlying urothelium. In IC, this barrier is believed to be defective. PPS, being a GAG mimetic, is thought to adhere to the damaged urothelium and reconstitute a functional barrier, thereby reducing mucosal permeability and irritation. This “barrier repair” model resonates deeply with functional and integrative medicine paradigms, where restoring epithelial and mucosal integrity is a foundational therapeutic principle.

Standard dosing is 100 mg three times daily (300 mg/day), taken on an empty stomach. Clinical response may take 3 to 6 months, and current recommendations advise discontinuation if no improvement is seen within 6 months. Evidence for efficacy in IC remains mixed, with some randomized trials showing benefit and others failing to demonstrate superiority over placebo.

PART III — ARTHRITIS: THE DMOAD STORY

Overview: A Disease-Modifying Osteoarthritis Drug Candidate

Perhaps the most clinically advanced off-label application of PPS is in osteoarthritis (OA). PPS has been described as a disease-modifying OA drug (DMOAD) candidate based on data from both veterinary medicine (equine and canine studies) and emerging human trials. Administered as a series of subcutaneous or intramuscular injections, PPS has demonstrated reduced pain, improved joint function, and regression of bone marrow lesions in human imaging studies.

Unlike NSAIDs, which mask symptoms without addressing disease biology, PPS engages the root drivers of cartilage destruction. To understand why this matters, we need to look at the molecular machinery of joint degeneration.

The Aggrecan Problem

The cartilage extracellular matrix is a sophisticated architectural system. At its core is aggrecan—a massive proteoglycan consisting of a core protein decorated with chondroitin sulfate and keratan sulfate chains, anchored to hyaluronic acid via link protein. The high negative charge density of these sulfated GAGs creates the osmotic swelling pressure that gives cartilage its compressive stiffness and shock-absorbing properties. When aggrecan is degraded and lost from the matrix, cartilage loses its functional integrity and the OA cascade accelerates.

The Aggrecanase Story: ADAMTS-4 and ADAMTS-5

For decades, matrix metalloproteinases (MMPs) were considered the primary villains in cartilage destruction. Then, in 1991, Sandy and colleagues identified a distinct proteolytic activity that cleaved aggrecan at the Glu373–Ala374 bond in the interglobular domain, generating a characteristic “NITEGE” neoepitope. This activity was named aggrecanase, and the enzymes responsible—members of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) family—are now considered the dominant drivers of early cartilage proteoglycan loss in both osteoarthritis and rheumatoid arthritis.

Six ADAMTS species exhibit aggrecanase activity: ADAMTS-1, -4, -5, -8, -9, and -15. Of these, ADAMTS-4 and ADAMTS-5 are the most clinically relevant. ADAMTS-5 is constitutively expressed in chondrocytes and synoviocytes, while ADAMTS-4 expression is induced by pro-inflammatory cytokines such as IL-1 and TNF-α. Blocking these enzymes has been a major goal of DMOAD development for over two decades.

PPS as a Direct Aggrecanase Inhibitor

The seminal work by Takizawa and colleagues (FEBS Letters, 2008) demonstrated that calcium pentosan polysulfate (CaPPS) directly inhibits the enzymatic activity of ADAMTS-4 in osteoarthritic chondrocytes, without altering ADAMTS mRNA expression. The inhibition is mediated by binding of PPS to specific regions of the C-terminal ancillary domain of the enzyme—specifically, the thrombospondin type-1 repeat, cysteine-rich domain, and spacer domain. Synthetic peptides corresponding to these regions compete with immobilized CaPPS for binding.

Troeberg and colleagues (FASEB Journal, 2008) extended this work, characterizing CaPPS as a “multifaceted exosite inhibitor” of aggrecanases. In cartilage explant studies using both porcine and human osteoarthritic tissue, CaPPS protected against IL-1α– and retinoic acid–induced aggrecan breakdown in a dose-dependent manner (10–100 μg/mL). Importantly, CaPPS did not adversely affect overall chondrocyte metabolism, as demonstrated by preserved sulfate and leucine incorporation and normal lactate production.

TIMP-3: PPS Amplifies the Body’s Endogenous Brake

Beyond direct enzyme inhibition, PPS possesses a second, equally important mechanism: it selectively upregulates the production of tissue inhibitor of metalloproteinases-3 (TIMP-3). TIMP-3 is unique among the TIMP family because it is a potent endogenous inhibitor not only of MMPs but also of aggrecanases—with Ki values against ADAMTS-4 and ADAMTS-5 in the subnanomolar range. TIMP-3 also inhibits TNF-α converting enzyme (ADAM-17), ADAM-10, and ADAM-12, making it a master regulator of metalloproteinase activity.

CaPPS has been shown to selectively enhance TIMP-3 production in rheumatoid synovial fibroblasts and gingival fibroblasts. The mechanism appears to involve PPS binding to negatively charged polysaccharide interaction sites on TIMP-3, stabilizing its interaction with the extracellular matrix and prolonging its local anti-proteolytic activity. This represents a sophisticated two-pronged attack: PPS directly inhibits the aggrecanases while simultaneously amplifying the body’s own most potent aggrecanase antagonist.

The Full Mechanistic Picture

The mechanistic portfolio of PPS in arthritis extends substantially beyond ADAMTS inhibition. From a functional medicine perspective, PPS simultaneously addresses multiple root drivers of joint degeneration: protease activity, cytokine signaling, matrix synthesis, pain transduction, microvascular flow, and regenerative capacity. The following table summarizes the major targets and pathways engaged by PPS in the arthritic joint:

Rheumatoid Arthritis: An Underappreciated Domain

While PPS is most commonly discussed in the context of osteoarthritis, its mechanistic profile is arguably even more relevant to rheumatoid arthritis. RA is characterized by cytokine-driven (IL-1, TNF-α) aggrecanase and MMP activity, synovial hyperplasia, and progressive joint destruction. PPS addresses each of these: it directly inhibits the relevant proteases, upregulates TIMP-3 in rheumatoid synovial fibroblasts, dampens NF-κB-mediated cytokine production, and reduces NGF-mediated bone pain. The clinical literature in RA is thinner than in OA, but the biology is compelling.

Mesenchymal Stem Cells and Regenerative Potential

PPS has been shown to bind STRO-1⁺ mesenchymal precursor cells from adult bone marrow and promote their proliferation and chondrogenic differentiation (Ghosh et al., Arthritis Research & Therapy, 2010). This property has driven interest in PPS as a component of tissue-engineering bioscaffolds and as an adjunct to stem-cell–based regenerative protocols. The FGF-signaling enhancement mediated by PPS is particularly relevant, as FGF2 is a well-characterized driver of MSC expansion and chondrogenesis.

Clinical Evidence in Human Arthritis

Human Studies

Ghosh, Edelman, March, and Smith (Current Therapeutic Research, 2005) conducted a randomized, double-blind, placebo-controlled pilot study of PPS in knee osteoarthritis, demonstrating symptomatic improvement and favorable safety. Kumagai and colleagues (BMC Clinical Pharmacology, 2010) performed an open-label trial in 20 patients with knee OA (Kellgren-Lawrence grades 1–3) using six weekly subcutaneous injections of pentosan at 2 mg/kg, with patients followed for up to 52 weeks. The study reported cartilage improvement on imaging and sustained symptomatic benefit, supporting the DMOAD hypothesis.

Veterinary Evidence

PPS has an extensive track record in veterinary orthopedics. In dogs, subcutaneous PPS at 3 mg/kg has shown significant clinical improvement in established osteoarthritis, with improvements correlating with plasma markers of fibrinolytic activity. In equine medicine, PPS (marketed as Cartrophen Vet, Pentosan, and Zydax) is widely used for joint disease, with supporting evidence for reduced lameness and improved cartilage markers. This veterinary data provides a substantial body of safety and efficacy evidence that informs integrative clinical decision-making.

Spine and Tendon Applications

Preclinical data support PPS in intervertebral disc degeneration and tendinopathy, where it protects matrix integrity, inhibits protease activity, and supports post-surgical repair. These applications are particularly compelling for the integrative practitioner managing chronic spinal pain, as they address the biological substrate of degeneration rather than simply masking symptoms.

PART IV — ANTIMICROBIAL ACTIVITY

A Broad-Spectrum GAG Decoy

Many pathogens—viruses, parasites, and certain bacteria—exploit cell-surface heparan sulfate proteoglycans as attachment factors or co-receptors during host cell invasion. PPS, as a highly sulfated heparin mimetic, competes with native heparan sulfate for pathogen binding, thereby blocking attachment and entry. This unifying mechanism explains the remarkably broad antimicrobial spectrum of PPS, which spans enveloped viruses, the malaria parasite, uropathogenic bacteria, and even prion proteins.

In essence, PPS acts as a decoy GAG—occupying the binding sites that pathogens would otherwise use to attach to human cells.

Antiviral Activity

SARS-CoV-2: A Strong In Vitro Inhibitor

The COVID-19 pandemic renewed interest in sulfated polysaccharides as antivirals. Heparan sulfate on the surface of human cells is a crucial co-receptor for SARS-CoV-2 binding to ACE2—it anchors the virus and facilitates the conformational change in the spike protein that enables ACE2 engagement. Multiple independent studies have now demonstrated that PPS disrupts this interaction with high potency.

Using surface plasmon resonance, Zhang and colleagues (2022) showed that PPS inhibits spike protein receptor-binding domain (RBD) binding to immobilized heparin with an IC50 of approximately 35 nM—stronger than soluble heparin itself (IC50 56 nM). In cell-based assays using pseudotyped viral particles, PPS demonstrated robust antiviral activity against both wild-type and Delta variant SARS-CoV-2. Critically, PPS retained activity against all tested spike mutants, including E484Q, T478K, L452R, N501Y, and combinations thereof.

Ennemoser and colleagues (Biomedicines, 2022) further demonstrated that PPS binds both the spike protein and the ACE2 receptor in isothermal fluorescence titration experiments, and inhibits viral entry in Vero cells in a concentration-dependent manner comparable to enoxaparin. Bertini and colleagues confirmed that PPS was as effective as unfractionated heparin and more effective than LMWH on a weight-by-weight basis at inhibiting SARS-CoV-2 invasion.

Docking studies suggest that PPS, like heparin, interacts with positively charged amino acid residues in the spike protein (N354, R355, K356, R357), effectively occupying the site normally engaged by cell-surface heparan sulfate. Because PPS has lower anticoagulant activity than heparin, it has been proposed as a candidate for intranasal or oral prophylactic use—though no such product has reached clinical approval.

HIV-1: Multiple Mechanisms of Inhibition

PPS was identified as an anti-HIV agent in the early days of the AIDS epidemic. Baba and colleagues (1988) demonstrated that PPS is a potent and selective inhibitor of HIV-1 replication in vitro. Subsequent work revealed two distinct mechanisms.

First, PPS binds the HIV-1 Tat protein with high affinity (Kd = 9.0 nM), blocking its cell-surface interaction and internalization (Rusnati et al., Journal of Biological Chemistry, 2001). Tat is a pleiotropic heparin-binding viral protein released from infected cells that contributes to HIV pathogenesis and AIDS-associated complications, including Kaposi’s sarcoma. PPS inhibits Tat-induced neovascularization in chick chorioallantoic membrane assays, suggesting therapeutic potential as a Tat antagonist.

Second, PPS inhibits both protein tyrosine kinases (including p56ˡᶜᵏ, a lymphocyte-specific Src-family kinase) and serine/threonine kinases (including protein kinase C). This kinase inhibition is rapid, competitive with respect to ATP (Ki 5–20 μg/mL), and contributes to its antiviral effect by disrupting signaling pathways required for HIV-1 replication. These properties also underlie some of its anti-tumor activity.

Alphaviruses: The Most Clinically Advanced Antiviral Indication

Arthritogenic alphaviruses—notably Ross River virus (RRV) and chikungunya virus (CHIKV)—cause large epidemics of debilitating polyarthritis that can persist for months to years, with immunopathology resembling rheumatoid arthritis. There is currently no licensed specific treatment for alphaviral arthritis, making PPS’s demonstrated efficacy in this domain particularly significant.

Herrero and colleagues (Journal of Virology, 2015) showed in mouse models that RRV infection produces ADAMTS-4/5–mediated cartilage thinning and proteoglycan loss—mechanistically parallel to osteoarthritis. PPS treatment significantly reduced joint inflammation, cartilage damage, and joint swelling in both RRV- and CHIKV-infected mice, without affecting viral replication kinetics. The disease-modifying effect was mediated by early elevation of anti-inflammatory IL-10 and suppression of CCL-2, IL-6, IL-9, and G-CSF.

A Phase 2a randomized, double-blind, placebo-controlled clinical trial (Krishnan et al., BMC Musculoskeletal Disorders, 2021) evaluated subcutaneous PPS (2 mg/kg twice weekly for 6 weeks) in 20 patients with RRV-induced arthralgia. PPS was well tolerated, with injection site reactions the most common adverse event, and demonstrated improvements in hand grip strength, RAPID3 scores, and SF-36 quality of life. This remains one of the strongest human clinical signals for PPS as a disease-modifying agent in virally induced joint disease.

In Australia, injectable PPS is now available through the Therapeutic Goods Administration’s Special Access Scheme for patients with chronic RRV-induced arthritis who have no other treatment options.

Other Enveloped Viruses

The antiviral activity of PPS extends more broadly. Baba and colleagues (Antimicrobial Agents and Chemotherapy, 1988) demonstrated that sulfated polysaccharides including PPS are potent and selective inhibitors of herpes simplex virus (HSV), cytomegalovirus (CMV), vesicular stomatitis virus, and HIV. All of these pathogens depend on cell-surface heparan sulfate for attachment, and PPS competitively blocks this interaction.

PPS has also shown activity against human T-cell leukemia virus type 1 (HTLV-1). In a small clinical study, PPS treatment ameliorated motor function in HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP), with associated increases in serum soluble VCAM-1. In a mouse model of influenza A/PR8/34 pulmonary inflammation, PPS reduced lung inflammation through modulation of Th2 cytokines (IL-4, IL-5, IL-13), suggesting that its utility may extend beyond pure viral entry inhibition to include modulation of the inflammatory host response.

Antiparasitic Activity

Malaria

The asexual erythrocytic stage of Plasmodium falciparum depends on interactions with host cell-surface glycans for red blood cell invasion. Xiao and colleagues (1997) demonstrated that PPS, along with heparin, dextran sulfate, and fucoidan, inhibits malaria parasite growth with IC50 values of 1–11 μg/mL. Mechanistic studies indicated that PPS blocks merozoite invasion of erythrocytes rather than intracellular parasite maturation, consistent with a heparan sulfate–competitive mechanism at the red cell surface. Immobilization of heparin onto agarose beads preserved antimalarial activity, confirming that cellular uptake of the sulfated polysaccharide is not required.

Antibacterial Activity

Uropathogen Adherence and Bladder Barrier Function

The antibacterial activity of PPS in the genitourinary tract is mechanistically distinct from its antiviral effects. The healthy urothelium is protected by a glycosaminoglycan layer that resists bacterial adherence. Parsons and colleagues (Infection and Immunity, 1980) demonstrated in a rabbit bladder model that exogenous PPS can duplicate the antibacterial activity of native bladder surface mucin, reducing bacterial colonization by restoring the GAG barrier. Schamhart and colleagues subsequently showed that PPS modulates the interaction between bacteria and the luminal bladder surface. This mechanism contributes to the clinical benefit of PPS in interstitial cystitis and may have broader implications for recurrent UTI prevention in patients with disrupted urothelial barrier function.

Antiprion Activity

Prion diseases—including Creutzfeldt–Jakob disease (CJD), scrapie, and bovine spongiform encephalopathy—are caused by misfolded prion proteins (PrPᴼ) that propagate by templating the conversion of normal cellular prion protein (PrPᶜ) into the pathologic isoform. Cellular heparan sulfate proteoglycans serve as co-receptors in this process, interacting with the 37-kDa/67-kDa laminin receptor (LRP/LR) that mediates PrPᴼ binding.

PPS has been shown to inhibit PrPᴼ propagation in cell culture, prolong incubation times and survival in prion-infected mice, and reduce infectious prion protein deposition in the brain. The mechanism involves competitive displacement of endogenous heparan sulfate from the LRP/LR receptor. PPS has been used on compassionate grounds in human CJD, though controlled clinical trials have not demonstrated clear benefit—likely because treatment was initiated too late in the disease course.

Antimicrobial Activity at a Glance

PART V — ADDITIONAL FUNCTIONAL MEDICINE APPLICATIONS

Other Pleiotropic Effects of Interest

Beyond arthritis and antimicrobial activity, PPS has been investigated in a range of conditions that map well onto functional and integrative medicine concerns. The evidence in these domains ranges from early-phase human data to animal models and in vitro studies. None should be considered established clinical indications, but each represents a biologically plausible extension of known PPS mechanisms.

Cardiometabolic and Vascular Support

Experimental work suggests PPS may inhibit atherosclerotic progression and improve cardiac function through its lipid-clearing and endothelial-protective effects. The anticoagulant and fibrinolytic properties of PPS also improve microcirculatory dynamics. While these data remain preclinical, they align with the integrative medicine emphasis on endothelial function as a root cause of cardiovascular disease.

Kidney and Diabetic Complications

PPS has shown benefit in models of severe diabetic nephropathy, chronic kidney disease, and polycystic kidney disease through anti-inflammatory and microvascular mechanisms. The glycocalyx of the glomerular filtration barrier is rich in heparan sulfate proteoglycans, and PPS may support this barrier in a manner analogous to its effect on the bladder urothelium—a conceptual bridge that functional medicine practitioners will find intuitive.

Oncology and Anti-Metastatic Effects

PPS demonstrates anti-tumor activity in various cancer models and inhibits metastasis in preclinical systems, in part through interference with tumor-endothelial interactions and heparanase-mediated pathways. In vitro reversal of malignant phenotype in prostate cancer cells has been described. These findings are mechanistically interesting but far from clinical application. The integrative oncologist should be aware of this literature while recognizing its early-stage nature.

Gut and Microbiome Modulation

PPS has been used for painful bowel syndromes and may support gut mucosal protection through its GAG-mimetic barrier effects. Some reports note that gut bacteria can convert pentosan into xylo-oligosaccharides with prebiotic potential, suggesting a role in microbiome modulation. This aligns with the functional medicine emphasis on barrier repair, microbial diversity, and colon cancer risk reduction, though human outcome data remain limited.

Neuroinflammation

PPS reduces neuroinflammatory signaling and protects neural tissue in experimental models, likely through cytokine modulation and microvascular effects. These findings have raised interest in neurodegenerative conditions and chronic pain syndromes. The HTLV-1 neurologic disease data discussed earlier provide one of the few human clinical signals in this domain.

Genitourinary: Beyond Interstitial Cystitis

PPS has been explored for benign prostatic hyperplasia and non-bacterial prostatitis, where it may decrease smooth-muscle proliferation and protect prostatic tissue. These applications are logical extensions of its GAG-mimetic and anti-inflammatory properties but remain investigational.

PART VI — SAFETY AND MONITORING

The Maculopathy Question

Every clinician prescribing PPS must understand the retinal toxicity risk. Long-term oral PPS use has been associated with a unique, progressive pigmentary maculopathy that was first formally described in 2018. In June 2020, the FDA updated the Elmiron label to include a warning about retinal pigmentary changes, and this concern has only grown with subsequent research.

Pentosan Polysulfate Maculopathy (PPSM)

PPSM is a slowly progressive retinal disorder affecting the retinal pigment epithelium (RPE) and the RPE-photoreceptor interface. Symptoms include difficulty with dark adaptation, night vision impairment, blurred vision, and metamorphopsia. Characteristic findings on multimodal retinal imaging include mottled hypo- and hyper-autofluorescence centered on the fovea, RPE atrophy, and subretinal deposits.

A 2025 meta-analysis of over 140,000 patients confirmed a dose-dependent relationship: even cumulative exposures below 500 g (approximately 4.6 years at standard dosing) were associated with a twofold higher risk of PPSM compared to non-users, while exposures exceeding 2,000 g (approximately 18 years) conferred an eightfold higher risk. Critically, maculopathy progression has been documented even years after discontinuation of PPS, making this a potentially irreversible toxicity.

An important clinical nuance: injectable PPS protocols used in osteoarthritis and alphaviral arthritis carry substantially lower cumulative exposure than chronic oral dosing for interstitial cystitis. A 6-week course of subcutaneous PPS at 2 mg/kg twice weekly delivers roughly 0.2–0.3 g cumulative—orders of magnitude below the maculopathy threshold of 500 g. This consideration may favor injectable PPS for non-IC indications when clinically appropriate.

Other Adverse Effects

Common: Gastrointestinal upset (diarrhea, heartburn, abdominal pain), headache, reversible hair loss, and rash.

Hematologic: Increased bruising and bleeding risk due to its heparinoid anticoagulant and fibrinolytic properties. PPS should be used with caution or avoided in patients on concurrent anticoagulant or antiplatelet therapy, in those with bleeding disorders, and perioperatively.

Hepatic: Abnormal liver function tests have been reported at low frequency. Patients with significant hepatic impairment warrant closer monitoring.

Contraindications: Known hypersensitivity to PPS or structurally related compounds; active bleeding disorders; significant hepatic or renal impairment.

PART VII — CLINICAL INTEGRATION AND BOTTOM LINE

Integrating PPS Into Functional Medicine Practice

From the functional medicine vantage point, PPS occupies a unique pharmacologic niche: it is one of the few available agents that simultaneously supports barrier integrity, modulates inflammation through non-COX mechanisms, enhances microvascular function, and promotes tissue regeneration. This makes it a conceptually compelling tool for the complex, multisystem patients that integrative practitioners frequently encounter.

The two major domains explored in this review—arthritis and antimicrobial activity—are biologically inseparable. Viral arthritides caused by alphaviruses, HTLV-1, and potentially other pathogens share the same molecular machinery with osteoarthritis and rheumatoid arthritis: cytokine-driven ADAMTS and MMP activation, proteoglycan loss, and NGF-mediated bone pain. PPS addresses all of these pathways regardless of the upstream trigger. For the functional medicine clinician managing patients with post-infectious polyarthritis (including Long COVID–associated joint syndromes, post-chikungunya arthralgia, or post-Lyme arthralgia), this mechanistic breadth is particularly compelling.

Where the Evidence Is Strongest

• Interstitial cystitis — FDA-approved; oral 100 mg TID; the only indication with regulatory backing.
• Knee osteoarthritis — RCT and open-label human data using subcutaneous PPS (2 mg/kg weekly × 6) with sustained benefit at 52 weeks.
• Ross River virus–induced arthralgia — Phase 2a RCT demonstrating improved function and quality of life. Available in Australia via Special Access Scheme.
• Chikungunya-induced arthralgia — Strong preclinical mouse model data; active clinical development.
• Intervertebral disc degeneration, tendinopathy — Preclinical and veterinary evidence with human translation in progress.

Where the Evidence Is Promising but Preclinical

SARS-CoV-2 prophylaxis, post-acute COVID-19 syndromes, HIV adjunctive therapy, HTLV-1 neurologic disease, malaria prophylaxis, prion disease, diabetic nephropathy, atherosclerosis, oncology, and broad-spectrum antiviral applications all have strong mechanistic rationale but lack definitive controlled human outcome data. These remain areas of academic and investigational interest rather than established clinical indications.

Clinical Bottom Line

Selected References

Chemistry, Classification, and Overview

1. Smith MM, Melrose J. Pentosan polysulfate affords pleotropic protection to multiple cells and tissues. Pharmaceuticals (Basel). 2023;16(3):437. PMID: 36986536. [PMC10132487]

2. Linhardt RJ et al. Bottom-up and top-down profiling of pentosan polysulfate. Analyst. 2019;144(16):4793-4806. [PMC6682433]

3. DrugBank. Pentosan polysulfate sodium (DB00686). go.drugbank.com.

Interstitial Cystitis (FDA-Approved Indication)

4. U.S. Food and Drug Administration. Elmiron (pentosan polysulfate sodium) prescribing information. Revised July 2024.

5. Parsons CL, Mulholland SG. Successful therapy of interstitial cystitis with pentosanpolysulfate. J Urol. 1987;138(3):513-516.

Arthritis Mechanisms

6. Takizawa M, Yatabe T, Okada A, et al. Calcium pentosan polysulfate directly inhibits enzymatic activity of ADAMTS4 (aggrecanase-1) in osteoarthritic chondrocytes. FEBS Lett. 2008;582(20):2945-2949. PMID: 18671975.

7. Troeberg L, Fushimi K, Khokha R, et al. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J. 2008;22(10):3515-3524. PMID: 18632849.

8. Munteanu SE, Ilic MZ, Handley CJ. Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures. Arthritis Rheum. 2000;43(10):2211-2218. PMID: 11037880.

9. Fosang AJ, Little CB. Drug Insight: aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheumatol. 2008;4(8):420-427.

10. Ghosh P, Wu J, Shimmon S, et al. Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells. Arthritis Res Ther. 2010;12(1):R28.

11. Ghosh P, Edelman J, March L, Smith M. Effects of pentosan polysulfate in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res. 2005;66(6):552-571.

12. Kumagai K, Shirabe S, Miyata N, et al. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis—an open clinical trial. BMC Clin Pharmacol. 2010;10:7.

13. Read RA, Cullis-Hill D, Jones MP. Systemic use of pentosan polysulfate in the treatment of osteoarthritis. J Small Anim Pract. 1996;37(3):108-114.

Antiviral Activity

14. Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 1988;32(11):1742-1745.

15. Rusnati M, Urbinati C, Caputo A, et al. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem. 2001;276(25):22420-22425. PMID: 11304529.

16. Mahalingam R, Adhikari-Devkota A, Ghosh D. Pentosan polysulfate, a potent anti-HIV and anti-tumor agent, inhibits protein serine/threonine and tyrosine kinases. Biochem Biophys Res Commun. 1993;192(1):7-13. PMID: 7683745.

17. Zhang Q, Pavlinov I, Ye Y, et al. Potential anti-SARS-CoV-2 activity of pentosan polysulfate and mucopolysaccharide polysulfate. Pharmaceuticals. 2022;15(2):258. PMID: 35215371.

18. Ennemoser M, Rieger J, Muttenthaler E, et al. Enoxaparin and pentosan polysulfate bind to the SARS-CoV-2 spike protein and human ACE2 receptor, inhibiting Vero cell infection. Biomedicines. 2022;10(1):49.

19. Bertini S, Alekseeva AA, Elli S, et al. Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding. PMID: 35322395.

20. Herrero LJ, Foo SS, Sheng KC, et al. Pentosan polysulfate: a novel glycosaminoglycan-like molecule for effective treatment of alphavirus-induced cartilage destruction and inflammatory disease. J Virol. 2015;89(15):8063-8076. PMID: 26018160.

21. Krishnan R, Duiker M, Rudd PA, et al. Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. BMC Musculoskelet Disord. 2021;22(1):271. PMID: 33711991.

22. Rudd PA, Lim EXY, Stapledon CJM, et al. Pentosan polysulfate sodium prevents functional decline in chikungunya infected mice by modulating growth factor signalling and lymphocyte activation. PLoS One. 2021;16(8):e0255125.

Antiparasitic, Antibacterial, and Antiprion Activity

23. Xiao L, Yang C, Patterson PS, et al. Saccharide anions as inhibitors of the malaria parasite. Glycoconj J. 1997;14(3):335-344. PMID: 9249145.

24. Parsons CL, Pollen JJ, Anwar H, Stauffer C, Schmidt JD. Antibacterial activity of bladder surface mucin duplicated in the rabbit bladder by exogenous glycosaminoglycan (sodium pentosanpolysulfate). Infect Immun. 1980;27(3):876-881.

25. Dealler S, Rainov NG. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease. IDrugs. 2003;6(5):470-478.

26. Doh-Ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol. 2004;78(10):4999-5006.

Safety and Maculopathy

27. Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology. 2018;125(11):1793-1802.

28. Bae SS, Sodhi M, Maberley D, et al. Risk of maculopathy with pentosan polysulfate sodium use. Br J Clin Pharmacol. 2022;88:3428-3433.

29. Santina A et al. Pentosan polysulfate sodium maculopathy: final analysis of a prospective cohort, updated review, and association with inflammatory bowel disease. Surv Ophthalmol. 2024;70:583-592.

30. Hall BP et al. Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality. PubMed. 2025. PMID: 40962246.

31. Wang B et al. Post-marketing safety of pentosan polysulfate sodium: a 21-year pharmacovigilance analysis of the FAERS database. Front Med. 2026;12:1725094.

32. U.S. Food and Drug Administration. Elmiron labeling update (retinal pigmentary changes warning). June 2020.

Yoon Hang Kim MD •  www.directintegrativecare.com

Membership-Based Telemedicine  •  Root-Cause Integrative Medicine